Reversible Splenial Lesion Syndrome (RESLES) After Chemotherapy of Oral Tegafur-uracil in a Female With Locally Rectal Adenocarcinoma. Issue 4 (December 2020)

• Record Type: Journal Article
• Authors: Ge, Yu-Xing; Lin, Ying-Ying; Bi, Qian-Qian; Chen, Yu-Juan
• Is Part Of: Cognitive and behavioral neurology. Volume 33:Issue 4(2020)
• Publication Date: 2020-12
• Subjects: RESLES -- rectal adenocarcinoma -- tegafur -- anti-CV2; Neuropsychiatry -- Periodicals; Clinical neuropsychology -- Periodicals; 616.8005
• DOI: 10.1097/WNN.0000000000000250
• Languages: English
• ISSNs: 1543-3633

Abstract

Abstract : A 42-year-old woman with reversible splenial lesion syndrome (RESLES) and rectal adenocarcinoma presented with sudden-onset delirium after the sixth cycle of her chemotherapy drug, oral tegafur-uracil (300 mg/m 2 /day, days 1–14, with treatment cycle repeated every 21 days). Accompanied by the anti-CV2 antibody, paraphasia, and a loss of bimanual coordination, the patient's etiology and clinical manifestations of RESLES are unlike those of other reported cases of RESLES. Tegafur-uracil is an oral fluoropyrimidine that has a similar effect to 5-fluorouracil as an adjuvant treatment for colorectal cancer. The possibility that the toxicity of chemotherapeutic drugs may play a role in the pathogenesis of cytotoxic edema in the splenium of the corpus callosum and extracallosal white matter should be investigated further.